Indivior Pharmaceuticals, Inc. (E7P)
FSX
Real-time Data
06:00 AM
Day's Range
31.0052 wk Range
17.50Overview - E7P - Indivior Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
3.41B
P/E (Trailing)
‪12.97‬
PEG Ratio
‪0.02‬
Price / Sales (TTM)
‪2.74‬
Price / Book
‪-17.42‬
EV / EBITDA
‪6.93‬
Profitability
Gross Margin
‪85.42%‬
Profit Margin
‪26.74%‬
Operating Margin
‪46.93%‬
Return on Assets
‪26.39%‬
Return on Equity
‪-212.12%‬
Ownership
Shares Outstanding
118.00M
Float
116.03M
Held by Insiders
‪2.01%‬
Held by Institutions
‪98.93%‬
Price stats
Beta
‪1.13‬
50-Day Avg
‪34.06‬
200-Day Avg
‪30.09‬
Dividends
Payout Ratio
‪0.00%‬
Frequency
Annual
Market Cap - E7P - Indivior Pharmaceuticals, Inc.
Peers - E7P - Indivior Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on FSX.
- E7PFSXIndivior Pharmaceuticals, Inc.3.89BMarket Cap+46.97%52-week change13.94P/E (Trailing)‪26.74%‬Profit Margin
- ANLFSXAnalog Devices, Inc.152.94BMarket Cap+29.62%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- PARFSXParker-Hannifin Corporation107.87BMarket Cap+24.53%52-week change35.09P/E (Trailing)‪16.96%‬Profit Margin
- MRKFSXMerck KGaA59.69BMarket Cap+19.31%52-week change23.51P/E (Trailing)‪11.21%‬Profit Margin
- MRKCFSXMerck KGaA – Sponsored ADR59.12BMarket Cap+20.59%52-week change23.25P/E (Trailing)‪11.21%‬Profit Margin
- PY3FSXGalderma Group AG42.44BMarket Cap+22.10%52-week change58.15P/E (Trailing)‪14.57%‬Profit Margin
- H6D0FSXHaleon plc37.06BMarket Cap+1.29%52-week change20.06P/E (Trailing)‪14.55%‬Profit Margin
Profile Summary - E7P - Indivior Pharmaceuticals, Inc.
About
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medications for treating opioid use disorder and related substance dependence. Its core products include SUBLOCADE, a once-monthly extended-release…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
